Resource impact statement
Cancer Drugs Fund technology
NICE has recommended niraparib for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults, only if:
- they have a germline BRCA mutation and have had 2 courses of platinum-based chemotherapy or
- they do not have a germline BRCA mutation and have had 2 or more courses of platinum-based chemotherapy and
- the conditions in the managed access agreement for niraparib are followed.
Niraparib will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and TESARO have a commercial access agreement that makes niraparib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of niraparib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires in 2020 or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that around 750 people per year are eligible for treatment with niraparib.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 04 July 2018